Navigation Links
Instrumentation Laboratory Introduces Fully Automated HemosIL® AcuStar HIT Assay Panel in Europe and International Regions
Date:2/14/2012

BEDFORD, Mass., Feb. 14, 2012 /PRNewswire/ -- Instrumentation Laboratory (IL) today announced the release of their new HemosIL AcuStar HIT Assay Panel assay as a European CE IVD Mark product under the European Directive on in vitro Diagnostic Medical Devices.  This fully automated panel includes HemosIL AcuStar HIT-IgG(PF4-H) and HemosIL AcuStar HIT-Ab(PF4-H) assays.    

(Logo: http://photos.prnewswire.com/prnh/20100803/NE44435LOGO)

HemosIL AcuStar HIT assays are the first on-demand, fully automated, chemiluminescent reagents on a hemostasis testing system for the detection of antibodies associated with Heparin-Induced Thrombocytopenia (HIT).  They provide enhanced detection of HIT antibodies in specialty and hospital hemostasis laboratories.  Unlike existing manual processes, the ready-to-use, cartridge-based assays offer results in approximately 30 minutes -- on-demand, 24/7 -- allowing clinicians to make timely, well-informed therapeutic decisions.  In addition, pre-calibrated reagent cartridges offer significant time- and cost- efficiencies.  Chemiluminescent technology provides analytical excellence through an expansive working range for high sensitivity and precision. 

"We are proud to be at the forefront of HIT testing solutions," said Remo Tazzi, Director of Hemostasis Marketing at IL. "Arming healthcare providers with better diagnostic tools is our mission, and this test panel is an excellent example of that.  Now, management decisions for patients at risk for HIT can be made faster and more effectively than ever before, leading to significant time- and cost-efficiencies, as well as enhanced patient care."

This is the second panel of assays that has been commercialized on the ACL AcuStar system.   The first is the highly sensitive, fully automated Antiphospholipid Syndrome (APS) panel.  The assays in this panel provide a full clinical picture to distinguish APS and other thrombotic disorders efficiently and effectively, 24/7.   APS is one of the most common autoimmune diseases, occurring in 1-5% of the general population.  Clinical manifestations include vascular thrombosis and related sequelae (eg, stroke, pulmonary embolism, myocardial infarction) and pregnancy complications.  While approximately 10-15% of these events result from APS, there are many other conditions to consider when determining root cause.  Therefore, accurate and rapid diagnosis is essential when managing these critically ill patients. 

About HIT

HIT is a severe immunologic adverse reaction to Heparin, paradoxically resulting in venous and/or arterial thrombosis.  It is one of the most common of all adverse drug effects, due to the sheer volume of patients receiving heparin therapy.  Approximately 0.2–2.0% of patients treated with heparin (over 12 million patients/year in the US, alone) develop HIT.  If HIT is untreated, risk for serious sequelae (eg, stroke, pulmonary embolism, death) increases significantly.  Positive outcomes depend on early and accurate diagnosis and prompt initiation of alternative anticoagulants.

HemosIL AcuStar HIT assays are not currently 510(k) cleared.

Instrumentation Laboratory (www.ilus.com), founded in 1959, is a worldwide developer, manufacturer and distributor of in vitro diagnostic instruments, related reagents and controls for use primarily in hospitals and independent clinical laboratories.  The company's product lines include critical care systems, hemostasis systems and information management systems.  IL's GEM® product offerings, part of the critical care line, include the GEM Premier™ 4000 analyzer with Intelligent Quality Management (iQM®), GEM Premier 3500, GEMweb® Plus Custom Connectivity, and complementary products GEM PCL Plus, a portable coagulation analyzer, GEM OPL CO-Oximeter, and GEMdraw arterial blood samplers.  IL's hemostasis portfolio includes the ACL TOP® Family of Hemostasis Testing Systems, fully automated, high-productivity analyzers, including the ACL TOP 700, ACL TOP 700 LAS, ACL TOP 700 CTS, and ACL TOP 500 CTS.  IL also offers the new ACL AcuStar®, ACL ELITE®, other hemostasis analyzers and the HemosIL® line of reagents.  IL is based in Bedford, Massachusetts.

The Instrumentation Laboratory logo, GEM, iQM, HemosIL, ACL TOP, ACL ELITE, ACL AcuStar and Premier are trademarks of Instrumentation Laboratory Company and/or one of its subsidiaries or parent companies, and may be registered in the United States Patent and Trademark Office and in other jurisdictions.  All other product names, company names, marks, logos, and symbols are trademarks of their respective owners.
                                                                               


'/>"/>
SOURCE Instrumentation Laboratory
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Instrumentation Laboratory Introduces Automated HemosIL VWF Ristocetin Cofactor Activity Assay in Europe and International Regions
2. Unity Management Group Receives Large Purchase Order for their AIM Instrumentation Package From Barr Laboratories, Subdivision of TEVA Pharmaceuticals (NASDAQ: TEVA)
3. Premier Awards Sixth Consecutive Contract to Instrumentation Laboratory for Critical Care Portfolio
4. IVD Technology Announces Educational Lecture Webcast: Challenges in Clinical Lab Automation and IVD Instrumentation Development
5. Instrumentation Laboratory Appoints Ramon E. Benet New Chief Executive Officer
6. Instrumentation Laboratory Achieves Record Sales in 2010
7. Global Ophthalmic Instrumentation Industry
8. Advancements in GYN Oncology; Instrumentation and Techniques to be Presented by Nicholas C. Lambrou, M.D. of Miami
9. Reportlinker Adds Global Biotechnology Instrumentation Industry
10. Reportlinker Adds Global Orthopedic Instrumentation Industry
11. Global Ophthalmic Instrumentation Industry
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... CHICAGO , Sept. 28, 2017 Hill-Rom ... quarter 2017 earnings conference call and webcast on Friday, ... 8:00 a.m. (EDT) and ending at approximately 8:30 a.m. ... to discussing the company,s 2017 financial performance and guidance ... growth opportunities, initiatives to enhance operational performance, and long-range ...
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
(Date:9/23/2017)... -- Janssen Biotech, Inc. (Janssen) announced today that it ... Food and Drug Administration (FDA) for the Biologics License ... of moderately to severely active rheumatoid arthritis (RA). The ... to further evaluate the safety of sirukumab in the ... "We are disappointed by ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of a ... “The Journey: From the Mountains to the Mission Field” is the creation of published ... all ages and currently teaches a class of ladies at her church, which she ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of ... announced today its plans to open a flagship location in Covington, LA at 401 ... Rooms To Go store next to Office Depot in the Holiday Square shopping center. ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... AccentCare, a leader in post-acute health care, have expanded their existing home health ... Home Health. , AccentCare has been operating a joint venture home health company ...
(Date:10/12/2017)... ... , ... Leading pediatric oncology experts at Children’s National Health System ... of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of the ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... $3,296 in property taxes a year. In some states—like New York, New Jersey, ... By contrast, many overseas retirement havens have extremely low property-tax rates, which contributes ...
Breaking Medicine News(10 mins):